Volume : 13, Issue : 10, October – 2026

Title:

ANTIHYPERGLYCEMIC EFFECT IN THE MANAGEMENT OF DIABETES MELLITUS

Authors :

Shubhangi Ganpat Atole*, Bhumika santosh Bhagwat, Aishwarya Dnyaneshwar Takale, Dr. Vijay Sonawane

Abstract :

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin resistance, or a combination of both. The increasing global prevalence of diabetes has created a need for effective, safe, and accessible therapeutic strategies to achieve glycemic control and reduce diabetes-associated complications. This review aims to discuss the antihyperglycemic effects of conventional and emerging therapeutic agents, emphasizing their mechanisms of action, clinical applications, safety profiles, and future perspectives in diabetes management. Relevant scientific literature, clinical studies, review articles, and established clinical guidelines concerning diabetes pathophysiology, glucose-lowering pharmacotherapy, and natural products were considered to develop a narrative overview of current therapeutic approaches. Antihyperglycemic agents reduce blood glucose through several mechanisms, including suppression of hepatic glucose production, stimulation of insulin secretion, improvement of insulin sensitivity, enhancement of incretin activity, inhibition of intestinal carbohydrate digestion, and promotion of urinary glucose excretion. Major drug classes include biguanides, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin preparations. Emerging approaches, including dual incretin receptor agonists and advanced insulin delivery systems, offer additional therapeutic opportunities. Medicinal plants and naturally derived compounds have also demonstrated potential antihyperglycemic activity; however, their clinical effectiveness and safety require further rigorous evaluation. Treatment selection must consider glycemic efficacy, hypoglycemia risk, body-weight effects, cardiovascular and renal outcomes, adverse reactions, and patient-specific requirements. Individualized antihyperglycemic therapy, combined with lifestyle modification and regular monitoring, is essential for effective diabetes management. Continued research, high-quality clinical trials, and improved access to evidence-based treatments may further enhance therapeutic outcomes and reduce the long-term burden of diabetes mellitus.
Keywords: Diabetes mellitus; antihyperglycemic agents; hyperglycemia; insulin resistance; glycemic control; antidiabetic drugs; medicinal plants; diabetes management.

Cite This Article:

Please cite this article in press Shubhangi Ganpat Atole et al., Antihyperglycemic Effect In The Management Of Diabetes Mellitus.,. Indo Am. J. P. Sci, 2026; 13(10).

REFERENCES:

1. American Diabetes Association Professional Practice Committee for Diabetes. 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27–S49.
2. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795. doi:10.2337/db09-9028.
3. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):6275. doi:10.3390/ijms21176275.
4. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133–2223. doi:10.1152/physrev.00063.2017.
5. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068–1083. doi:10.1016/S0140-6736(13)62154-6.
6. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019. doi:10.1038/nrdp.2015.19.
7. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem. 2004;279(41):42351–42354. doi:10.1074/jbc.R400019200.
8. World Health Organization. Classification of diabetes mellitus. Geneva: World Health Organization; 2019. Available from: https://www.who.int/publications/i/item/classification-of-diabetes-mellitus
9. International Diabetes Federation. IDF Diabetes Atlas. 11th ed. Brussels: International Diabetes Federation; 2025. Available from: https://diabetesatlas.org/
10. American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S183–S215. doi:10.2337/dc26-S009.
11. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi:10.2337/dci22-0034.
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
13. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. doi:10.1056/NEJMoa0806470.
14. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585. doi:10.1007/s00125-017-4342-z.
15. Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566–1576. doi:10.1007/s00125-017-4318-z.
16. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1(2):140–151. doi:10.1016/S2213-8587(13)70050-0.
17. Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515–531. doi:10.1210/er.2010-0029.
18. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21. doi:10.1111/dom.13129.
19. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165. doi:10.1016/j.cmet.2006.01.004.
20. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(Suppl 2):S127–S138. doi:10.2337/dcS13-2011.
21. Chao EC, Henry RR. SGLT2 inhibition—a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551–559. doi:10.1038/nrd3180.
22. Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab. 2012;38(2):89–101.
23. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001.
24. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes—state-of-the-art. Mol Metab. 2021;46:101102. doi:10.1016/j.molmet.2020.101102.
25. Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab. 2017;19(1):3–12.
26. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2018;41(12):2669–2701. doi:10.2337/dci18-0033.
27. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi:10.1056/NEJMoa1504720.
28. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827.
29. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi:10.1056/NEJMoa1611925.
30. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi:10.1056/NEJMoa1811744.
31. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. doi:10.1056/NEJMoa2022190.